- AbbVie’s ovarian cancer drug Elahere greenlighted for NHS availability Seeking Alpha —
- ADC Therapeutics falls on confirmatory trial data for lymphoma therapy Seeking Alpha —
- A tumor’s ‘signature’ reveals the key to treatment in precision oncology EL PAÍS —
- Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology City AM —
- Ovarian cancer: NHS approves ‘first in over 20 years’ drug that offers women more time and better quality of life Times Of India —
- First ovarian cancer treatment in two decades approved for NHS use in 'landmark' decision ITV —
- NHS approves first new ovarian cancer treatment for 20 years Sky News —
- Breakthrough ovarian cancer drug offers patients more time and better quality of life BBC News —
- Hope for thousands of ovarian cancer patients as new drug which slashes risk of death by a third is made available on the NHS Daily Mail —
- Life-prolonging drug for advanced ovarian cancer gets go-ahead in England The Guardian —
- 'Significant breakthrough' as new ovarian cancer treatment approved for NHS use The Standard —
- Fresh hope for ovarian cancer patients as new treatment given go-ahead LBC —
- Hundreds of women to benefit from breakthrough ovarian cancer treatment in UK The Independent —
Mirvetuximab soravtansine
Medication
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.
Also known as...
Elahere, IMGN853, and IMGN-853
Ovarian Cancer Drug Approved by NHS